Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Echinomycin: the first bifunctional intercalating agent in clinical trials.

B J Foster, K Clagett-Carr, D D Shoemaker

    Investigational New Drugs
    |January 1, 1985
    PubMed
    Summary

    Echinomycin, an antibiotic with antitumor properties, showed reversible toxicity in animal studies and early clinical trials. Further Phase II trials are underway to assess its efficacy and safety in various diseases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Canadian Surgery Forum.

    Canadian journal of surgery. Journal canadien de chirurgie·2022
    Same author

    Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009.

    Canadian journal of surgery. Journal canadien de chirurgie·2022
    Same author

    The role of citizen science in addressing grand challenges in food and agriculture research.

    Proceedings. Biological sciences·2018
    Same author

    Characterisation of white and black merino wools: a proteomics study.

    Animal : an international journal of animal bioscience·2018
    Same author

    Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017

    Area of Science:

    • Pharmacology
    • Oncology
    • Toxicology

    Background:

    • Echinomycin is a quinoxaline antibiotic derived from Streptomyces echinatus.
    • It exhibits antitumor activity against murine models like B16 melanoma and P388 leukemia.
    • Its mechanism involves bifunctional intercalation with double-stranded DNA.

    Purpose of the Study:

    • To evaluate the toxicologic profile of echinomycin in preclinical animal models (mice and dogs).
    • To summarize findings from Phase I clinical trials regarding echinomycin's safety and tolerability.
    • To provide a basis for ongoing Phase II clinical trials investigating echinomycin's therapeutic potential.

    Main Methods:

    • Toxicologic studies involved intravenous administration of echinomycin to CDF1 mice and beagle dogs at various dose ranges and schedules.

    Related Experiment Videos

  • Phase I clinical trials assessed safety and toxicity across different intravenous administration schedules.
  • Data analysis focused on identifying major toxic effects and their reversibility.

    • Main Results:

    • Preclinical studies identified gastrointestinal, hepatic, and lymphoreticular systems as primary targets of echinomycin toxicity.
    • Toxic effects in dogs were largely reversible, except at the highest dose with prolonged administration.
    • Clinical trials reported nausea, vomiting, reversible liver enzyme abnormalities, and allergic reactions as common adverse events.

    Conclusions:

    • Echinomycin demonstrates a toxicity profile primarily affecting the gastrointestinal, hepatic, and lymphoreticular systems.
    • Observed toxicities in both animal models and human trials appear manageable and often reversible.
    • The National Cancer Institute has initiated Phase II trials to further explore echinomycin's antitumor activity and refine its safety profile in diverse patient populations.